Showing 1521-1530 of 5771 results for "".
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Abionyx Pharma Announces Its Strategy in Ophthalmologyhttps://modernod.com/news/abionyx-pharma-announces-its-strategy-in-ophthalmology/2481506/France-based Abionyx Pharma announced announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. "The acquisition of IRIS Pharma, one of the world leaders in contract research in ophthalmology,
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b Trial of Optogenetic Therapy for RPhttps://modernod.com/news/nanoscope-therapeutics-announces-positive-topline-results-from-phase-2b-trial-of-optogenetic-therapy-for-rp/2481504/Nanoscope Therapeutics announced topline results from the phase 2b RESTORE clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-0
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for RP and LCA Gene Therapyhttps://modernod.com/news/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-12-clinical-trial-for-rp-and-lca-gene-therapy/2481499/Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 phase 1/2 trial. OCU400 is a gene therapy candidate for retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). “This approval moves us one step closer in our efforts to bri
- Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-second-pivotal-phase-3-data-on-nov03-perfluorohexyloctane/2481485/Bausch + Lomb and Novaliq announced that the American Journal of Ophthalmology has
- OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivityhttps://modernod.com/news/ocusciences-announces-publication-showing-potential-to-detect-retinal-diseases-with-high-sensitivity/2481484/OcuSciences announced a publication in
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- Graybug Announces Name and Trading Symbol Changehttps://modernod.com/news/graybug-announces-name-and-trading-symbol-change/2481478/Graybug Vision announced that it has changed its name to CalciMedica Inc., effective today. In connection with the name change, the company has changed its trading symbol to “CALC.” The company’s common stock will commence trading on March 21, 2023 on the Nasdaq Global
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked